Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

ABSTRACT:

Objectives

To evaluate the role of caveolin-1 (Cav-1) as a predictor of disease reclassification (DR) in men with early prostate cancer undergoing active surveillance (AS).

Patients and methods

We analysed archived plasma samples prospectively collected from patients with early prostate cancer in a single-institution AS study. Of 825 patients enrolled, 542 had ≥1 year of follow-up. Baseline and longitudinal plasma Cav-1 levels were measured using an enzyme-linked immunosorbent assay. Tumour volume or Gleason grade increases were criteria for DR. Logistic regression analyses were used to assess associations between clinicopathological characteristics and reclassification risk.

Results

In 542 patients, 480 (88.6%) had stage cT1c disease, 542 (100.0%) had a median prosta

SUBMITTER: Basourakos SP 

PROVIDER: S-EPMC6126916 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature